Synthesis of 2-aryl-4-(benzimidazol-2-yl)-1,2-dihydro[1,2,4]triazino-[4,5-a]benzimidazol-1-one derivatives with preferential cytotoxicity against carcinoma cell lines. 2008

Jakub Stýskala, and Libuse Stýskalová, and Jan Slouka, and Marián Hajdúch
Department of Organic Chemistry, Faculty of Science, Palacký University, Tr. Svobody 8, 771 46 Olomouc, Czech Republic.

In this paper we describe the preparation of some derivatives of 1,2,4-triazino[4,5-a]benzimidazol-1-ones (5 and 6), containing additional benzimidazole ring. These compounds were prepared using coupling reactions of diazonium salts with 1,1-bis(1-ethoxycarbonyl-benzimidazol-2-yl)methane (2) to obtain unstable hydrazones 4, which readily undergo cyclization. Interestingly, the selected compounds demonstrated preferential cytotoxic activities against human carcinoma and glioma cell lines compared with leukemic cells. They showed significant activity against multidrug-resistant P-glycoprotein expressing cell lines but had less effect on multidrug-resistance protein 1 positive and topoisomerase IIalpha negative leukemias.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001562 Benzimidazoles Compounds with a BENZENE fused to IMIDAZOLES.
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular

Related Publications

Jakub Stýskala, and Libuse Stýskalová, and Jan Slouka, and Marián Hajdúch
December 2011, Bioorganic & medicinal chemistry letters,
Jakub Stýskala, and Libuse Stýskalová, and Jan Slouka, and Marián Hajdúch
September 1989, Journal of pharmaceutical sciences,
Jakub Stýskala, and Libuse Stýskalová, and Jan Slouka, and Marián Hajdúch
December 2020, Molecules (Basel, Switzerland),
Jakub Stýskala, and Libuse Stýskalová, and Jan Slouka, and Marián Hajdúch
April 2003, Farmaco (Societa chimica italiana : 1989),
Jakub Stýskala, and Libuse Stýskalová, and Jan Slouka, and Marián Hajdúch
July 2015, Journal of chemical biology,
Jakub Stýskala, and Libuse Stýskalová, and Jan Slouka, and Marián Hajdúch
September 2017, Acta crystallographica. Section E, Crystallographic communications,
Jakub Stýskala, and Libuse Stýskalová, and Jan Slouka, and Marián Hajdúch
May 2021, Molecular diversity,
Jakub Stýskala, and Libuse Stýskalová, and Jan Slouka, and Marián Hajdúch
January 2004, Acta poloniae pharmaceutica,
Jakub Stýskala, and Libuse Stýskalová, and Jan Slouka, and Marián Hajdúch
August 2008, Bioorganic & medicinal chemistry letters,
Jakub Stýskala, and Libuse Stýskalová, and Jan Slouka, and Marián Hajdúch
January 2017, The Journal of organic chemistry,
Copied contents to your clipboard!